You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 17, 2025

CLINICAL TRIALS PROFILE FOR HYDROGEN PEROXIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Hydrogen Peroxide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00154635 ↗ Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease Unknown status Development Center for Biotechnology, Taiwan Phase 2 2005-09-01 A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti.
NCT00154635 ↗ Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease Unknown status Program Office, National Science & Technology, Biotechnology & Pharmaceuticals Phase 2 2005-09-01 A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti.
NCT00154635 ↗ Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease Unknown status Taipei Veterans General Hospital, Taiwan Phase 2 2005-09-01 A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti.
NCT00154635 ↗ Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease Unknown status National Taiwan University Hospital Phase 2 2005-09-01 A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti.
NCT00193908 ↗ Cavilon Breast Trial: Comparison of Cavilon Durable Barrier Cream to Glycerine ("Sorbolene") Cream Completed 3M Phase 3 2004-03-01 This study has patients using two different moisturising creams during radiation therapy after mastectomy. These are Cavilon and sorbolene. It is hypothesised that skin reactions may be reduced by the Cavilon cream compared to sorbolene.
NCT00193908 ↗ Cavilon Breast Trial: Comparison of Cavilon Durable Barrier Cream to Glycerine ("Sorbolene") Cream Completed Trans Tasman Radiation Oncology Group Phase 3 2004-03-01 This study has patients using two different moisturising creams during radiation therapy after mastectomy. These are Cavilon and sorbolene. It is hypothesised that skin reactions may be reduced by the Cavilon cream compared to sorbolene.
NCT00193908 ↗ Cavilon Breast Trial: Comparison of Cavilon Durable Barrier Cream to Glycerine ("Sorbolene") Cream Completed Trans-Tasman Radiation Oncology Group (TROG) Phase 3 2004-03-01 This study has patients using two different moisturising creams during radiation therapy after mastectomy. These are Cavilon and sorbolene. It is hypothesised that skin reactions may be reduced by the Cavilon cream compared to sorbolene.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Hydrogen Peroxide

Condition Name

Condition Name for Hydrogen Peroxide
Intervention Trials
COVID-19 6
Covid19 4
Tooth Discoloration 4
Bleeding Gum 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Hydrogen Peroxide
Intervention Trials
COVID-19 10
Dentin Sensitivity 8
Tooth Discoloration 6
Hypersensitivity 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Hydrogen Peroxide

Trials by Country

Trials by Country for Hydrogen Peroxide
Location Trials
United States 49
Brazil 10
United Kingdom 6
Egypt 5
Australia 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Hydrogen Peroxide
Location Trials
California 8
Texas 5
Tennessee 4
New York 4
Pennsylvania 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Hydrogen Peroxide

Clinical Trial Phase

Clinical Trial Phase for Hydrogen Peroxide
Clinical Trial Phase Trials
Phase 4 15
Phase 3 15
Phase 2/Phase 3 5
[disabled in preview] 59
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Hydrogen Peroxide
Clinical Trial Phase Trials
Completed 48
Not yet recruiting 19
Recruiting 13
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Hydrogen Peroxide

Sponsor Name

Sponsor Name for Hydrogen Peroxide
Sponsor Trials
Emphycorp 3
University of Milan 3
Aclaris Therapeutics, Inc. 3
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Hydrogen Peroxide
Sponsor Trials
Other 122
Industry 22
NIH 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Hydrogen Peroxide: Clinical Trials, Market Analysis, and Projections

Introduction to Hydrogen Peroxide in Clinical Trials

Hydrogen peroxide, a compound widely known for its antiseptic and bleaching properties, is being explored in various clinical trials for its potential to enhance cancer treatment, particularly when combined with radiotherapy.

Enhancing Radiotherapy with Hydrogen Peroxide

A significant study led by scientists at the University of Iowa, University of Texas Southwestern Medical Center, and Galera Therapeutics, Inc., has shown promising results in using a hydrogen peroxide-producing drug to boost the cancer-killing effect of radiotherapy. The drug, Avasopasem manganese, acts like the natural enzyme superoxide dismutase, converting superoxide into hydrogen peroxide. This process selectively kills cancer cells while protecting healthy tissue from radiation damage[1].

Clinical Trials for Cancer Treatment

In clinical trials, Avasopasem manganese has demonstrated synergy with high-dose radiotherapy, particularly in treating lung and pancreatic cancers. The study revealed that the drug, when combined with radiotherapy, can nearly double overall survival in patients with pancreatic cancer compared to those receiving a placebo plus the same radiotherapy[1].

Another trial, focused on breast cancer, is investigating the use of hydrogen peroxide contained within a gel (KORTUC) to make breast cancer more sensitive to radiotherapy. This trial involves injecting the hydrogen peroxide gel into the cancer before radiotherapy, which slowly releases the hydrogen peroxide, enhancing the effectiveness of the treatment[4].

Market Analysis of Hydrogen Peroxide

The global hydrogen peroxide market is experiencing significant growth driven by various end-use industries.

Current Market Size and Growth

As of 2024, the global hydrogen peroxide market was valued at approximately USD 3.49 billion and is projected to grow at a CAGR of 5.7% to reach USD 5.74 billion by 2033[2].

Key End-Use Industries

Hydrogen peroxide is widely used in several industries:

  • Healthcare: The demand for hydrogen peroxide in healthcare has surged, particularly for disinfection and sterilization, especially during the COVID-19 pandemic. Its use in wound care and as an antiseptic further fuels its adoption in personal healthcare products[3].
  • Pulp and Paper: Hydrogen peroxide is preferred for bleaching and cleaning processes due to its environmentally friendly properties, driving market growth in this sector[5].
  • Water Treatment: The use of hydrogen peroxide in wastewater treatment for disinfection and odor control is another significant driver of market growth[5].
  • Electronics and Textiles: Hydrogen peroxide is also used in these industries for various applications, contributing to the overall market expansion[2].

Regional Market Dynamics

The Asia Pacific region dominates the global hydrogen peroxide market, with countries like China and India experiencing rapid industrialization and urbanization. China's extensive use of hydrogen peroxide in the pulp and paper industry, along with its focus on environmental sustainability, drives the market in this region[5].

In North America, the U.S. hydrogen peroxide market is significant due to its wide use in healthcare, chemical synthesis, and other applications. The heightened focus on hygiene post-pandemic has further increased demand for hydrogen peroxide disinfectants[5].

Projections and Future Outlook

Market Growth Projections

The global hydrogen peroxide market is expected to continue growing at a CAGR of 5.2% to 6.2% from 2022 to 2030, driven by increasing demand from various end-use industries. The market is projected to reach USD 8.90 billion by 2031[3][5].

Emerging Trends and Opportunities

  • Sustainable Practices: The shift towards environmentally friendly bleaching agents in the pulp and paper industry and other sectors is expected to enhance hydrogen peroxide's appeal and market presence[5].
  • Healthcare Applications: The ongoing demand for disinfection and sterilization solutions, especially in healthcare settings, will continue to drive the market growth[3].
  • Industrial Expansion: Rapid industrialization in emerging economies and advancements in water treatment technologies will further fuel the demand for hydrogen peroxide[5].

Key Takeaways

  • Clinical Trials: Hydrogen peroxide-producing drugs like Avasopasem manganese show promise in enhancing the effectiveness of radiotherapy while protecting healthy tissue.
  • Market Growth: The global hydrogen peroxide market is expected to grow significantly, driven by demand from healthcare, pulp and paper, and water treatment industries.
  • Regional Dynamics: The Asia Pacific region, particularly China, and North America are key markets due to industrialization and a focus on sustainable practices.
  • Future Outlook: The market is projected to reach USD 8.90 billion by 2031, driven by emerging trends in sustainable practices and healthcare applications.

FAQs

What is the role of hydrogen peroxide in cancer treatment?

Hydrogen peroxide is being explored in clinical trials to enhance the cancer-killing effect of radiotherapy. Drugs like Avasopasem manganese produce hydrogen peroxide, which selectively kills cancer cells while protecting healthy tissue.

How is hydrogen peroxide used in the healthcare sector?

Hydrogen peroxide is widely used in healthcare for disinfection, sterilization, wound care, and as an antiseptic, particularly during health crises like the COVID-19 pandemic.

What are the key industries driving the hydrogen peroxide market?

The key industries include healthcare, pulp and paper, water treatment, electronics, and textiles, with a significant focus on sustainable practices and environmental sustainability.

Which region dominates the global hydrogen peroxide market?

The Asia Pacific region, particularly China and India, dominates the global hydrogen peroxide market due to rapid industrialization and urbanization.

What is the projected growth rate of the global hydrogen peroxide market?

The global hydrogen peroxide market is expected to grow at a CAGR of 5.2% to 6.2% from 2022 to 2030, reaching USD 8.90 billion by 2031.

Sources

  1. University of Iowa, "Hydrogen peroxide-producing drug boosts cancer-killing effect of radiotherapy", May 13, 2021.
  2. StraitsResearch, "Global Hydrogen Peroxide Market Size, Top Share, Report to 2033".
  3. Allied Market Research, "Hydrogen Peroxide Market Size, Share | Industry Forecast, 2031".
  4. Cancer Research UK, "A trial looking at hydrogen peroxide to help radiotherapy work better for breast cancer (KORTUC)".
  5. Grand View Research, "Hydrogen Peroxide Market Size, Share | Industry Report 2030".

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.